Fluoxetine combined with clorazepate dipotassium and behaviour modification for treatment of anxiety-related disorders in dogs

被引:14
|
作者
Pineda, S. [1 ]
Anzola, B. [1 ]
Olivares, A. [1 ]
Ibanez, M. [1 ]
机构
[1] Univ Complutense Madrid, Fac Vet, Clin Comportamiento Anim, Dept Prod Anim, E-28040 Madrid, Spain
来源
VETERINARY JOURNAL | 2014年 / 199卷 / 03期
关键词
Canine; Aggression; Anxiety; Clorazepate; Fluoxetine; CHEWABLE TABLETS; MANAGEMENT;
D O I
10.1016/j.tvjl.2013.11.021
中图分类号
S85 [动物医学(兽医学)];
学科分类号
0906 ;
摘要
The effectiveness of clorazepate dipotassium combined with fluoxetine and a behaviour modification programme for the treatment of anxiety disorders in dogs was investigated. Forty dogs with anxiety disorders were initially enrolled and 36 dogs completed the trial. Dogs were classified into two behavioural categories (anxious dogs with aggression and anxious dogs without aggression) according to their presenting complaints, and were also subdivided into males, females, juveniles and adults. The dog owners were provided with a behaviour modification plan for their dogs to be commenced in the first week of therapy. Clorazepate dipotassium was administered PO at 1.0 mg/kg every 24 h for 4 weeks, and fluoxetine was administered PO at 1.0 mg/kg every 24 h for 10 weeks. Therapy with both drugs was initiated simultaneously. Improvement was reported in 25/36 dogs. Significant differences in treatment effects were observed between anxious dogs with aggression and anxious dogs without aggression (P < 0.05). Positive correlations between owner compliance with the treatment plan and reported improvement achieved during three periods of study were also noted. (C) 2013 Elsevier Ltd. All rights reserved.
引用
收藏
页码:387 / 391
页数:5
相关论文
共 50 条
  • [1] Use of fluoxetine, diazepam, and behavior modification as therapy for treatment of anxiety-related disorders in dogs
    Ibanez, Miguel
    Anzola, Bernadette
    JOURNAL OF VETERINARY BEHAVIOR-CLINICAL APPLICATIONS AND RESEARCH, 2009, 4 (06) : 223 - 229
  • [2] Combined pharmacological therapy of alprazolam-fluoxetine for the treatment of anxiety-related problems in dogs
    Pineda-Gonzalez, Stefania
    Olivares-Moreno, Alvaro
    Anzola-Delgado, Bernadette
    Ibanez-Talegon, Miguel
    REVISTA CIENTIFICA-FACULTAD DE CIENCIAS VETERINARIAS, 2017, 27 (06): : 375 - 384
  • [3] SINGLE DAILY DOSE TREATMENT OF ANXIETY WITH CLOBAZAM OR DIPOTASSIUM CLORAZEPATE
    WALLIS, TD
    VALLEJONES, JC
    CRAVEN, JR
    HANKS, GW
    STONIER, PD
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1979, 7 : S123 - S127
  • [4] Anxiety-related disorders: An overview
    Riordan, Denise M.
    Singhal, Deepa
    JOURNAL OF PAEDIATRICS AND CHILD HEALTH, 2018, 54 (10) : 1104 - 1109
  • [5] Use of cannabidiol in anxiety and anxiety-related disorders
    Skelley, Jessica W.
    Deas, Crystal M.
    Curren, Zachary
    Ennis, Jonathan
    JOURNAL OF THE AMERICAN PHARMACISTS ASSOCIATION, 2020, 60 (01) : 253 - 261
  • [6] Novel pharmacological targets in drug development for the treatment of anxiety and anxiety-related disorders
    Sartori, Simone B.
    Singewald, Nicolas
    PHARMACOLOGY & THERAPEUTICS, 2019, 204
  • [7] The cerebellum in fear and anxiety-related disorders
    Moreno-Rius, Josep
    PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY, 2018, 85 : 23 - 32
  • [8] Anxiety-Related Disorders in the Context of Racism
    MacIntyre, M. Myriah
    Zare, Manzar
    Williams, Monnica T.
    CURRENT PSYCHIATRY REPORTS, 2023, 25 (02) : 31 - 43
  • [9] Update on treatments for anxiety-related disorders
    Lee, Hyun Jeong
    Stein, Murray B.
    CURRENT OPINION IN PSYCHIATRY, 2023, 36 (02) : 140 - 145
  • [10] Introduction - Remission of anxiety-related disorders
    Shelton, RC
    JOURNAL OF CLINICAL PSYCHIATRY, 2001, 62 : 3 - 4